RxDoctor Payments Data

Ivan Dankanich

Primary Care · Port Charlotte, FLNPI 1295182269

Payments from drug & device makers

$1,634in general payments, 2019–2025

Across 81 payments — averaging $20.17 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$411
  • Lilly USA, LLC$195
  • AbbVie$178
  • GSK$176
  • Amgen$107
  • Pfizer$107
  • plus $460 from 13 others

What the payments were for

  • Food & beverage$1,634100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,634 in reported general payments places this provider in the 80th percentile of 725 primary care providers in Florida.

See all primary care providers in Florida

Medicare billing

Part B allowed, 2024
$65,484
Medicare patients
187
Services billed
1,318

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide49$64,014
EliquisApixaban49$46,897
RybelsusSemaglutide26$46,531
JanuviaSitagliptin Phosphate18$28,177
TrulicityDulaglutide23$22,155
JardianceEmpagliflozin12$12,546
XareltoRivaroxaban18$12,020
Trelegy ElliptaFluticasone/Umeclidin/Vilanter12$9,641
Breo ElliptaFluticasone/Vilanterol20$8,387
SymbicortBudesonide/Formoterol Fumarate17$6,093
Rosuvastatin Calcium137$1,728
Asmanex HfaMometasone Furoate14$1,584
Novolin 70-30Insulin Nph Hum/Reg Insulin Hm12$1,546
Albuterol Sulfate HfaAlbuterol Sulfate86$1,497
Atorvastatin Calcium180$1,470

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$411$110,54475 claims
PfizerEliquis$107$46,89749 claims
Lilly USA, LLCTrulicity$195$22,15523 claims
GSKTrelegy Ellipta, Breo Ellipta$176$18,02832 claims
Boehringer IngelheimJardiance$16$12,54612 claims
Johnson & JohnsonXarelto$21$12,02018 claims
AstraZenecaSymbicort$28$6,09317 claims
AbbVieSynthroid$178$60211 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 725 primary care providers in Florida.

Other primary care in Port Charlotte

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →